Idexx LaboratoriesIDXX
IDXX
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
11% more first-time investments, than exits
New positions opened: 156 | Existing positions closed: 141
0% more funds holding in top 10
Funds holding in top 10: 12 [Q3] → 12 (+0) [Q4]
0% less funds holding
Funds holding: 1,100 [Q3] → 1,095 (-5) [Q4]
0.84% less ownership
Funds ownership: 88.54% [Q3] → 87.7% (-0.84%) [Q4]
19% less capital invested
Capital invested by funds: $36.5B [Q3] → $29.7B (-$6.76B) [Q4]
23% less repeat investments, than reductions
Existing positions increased: 332 | Existing positions reduced: 431
44% less call options, than puts
Call options by funds: $71.7M | Put options by funds: $129M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$510
21%
upside
Avg. target
$529
25%
upside
High target
$550
30%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Piper Sandler David Westenberg 49% 1-year accuracy 21 / 43 met price target | 21%upside $510 | Neutral Maintained | 10 Feb 2025 |
Barclays Balaji Prasad 32% 1-year accuracy 14 / 44 met price target | 23%upside $520 | Overweight Maintained | 4 Feb 2025 |
B of A Securities Michael Ryskin 60% 1-year accuracy 3 / 5 met price target | 27%upside $535 | Neutral Maintained | 4 Feb 2025 |
Morgan Stanley Erin Wright 60% 1-year accuracy 15 / 25 met price target | 30%upside $550 | Overweight Maintained | 29 Jan 2025 |
Financial journalist opinion
Based on 3 articles about IDXX published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Should You Retain IDEXX Stock in Your Portfolio for Now?
IDXX stays on investors' radar due to the strength of its CAG Diagnostics business.
Positive
Seeking Alpha
1 week ago
IDEXX Laboratories: Cancer Dx Launch In March 2025; Upgrading To 'Buy'
Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive significant growth and new revenue streams. IDEXX's share repurchase program is robust, with $837 million repurchased in FY24 and a plan for $1.5 billion in FY25.
Positive
Seeking Alpha
2 weeks ago
IDEXX Laboratories: A Top Dog In The Pet Care Market
The pet care industry is growing, with increasing pet ownership and spending, especially in emerging markets, providing IDEXX with significant growth opportunities. IDEXX Laboratories is the market leader with a highly profitable business model, operating leverage, and recurring revenues. Once a customer starts using an IDEXX instrument, it is tied to the IDEXX ecosystem.
Positive
Zacks Investment Research
1 month ago
Should You Hold IDEXX Stock in Your Portfolio for Now?
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
Neutral
Business Wire
1 month ago
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate and CAG Finance, will participate in a fireside chat at the virtual BofA Securities Animal Health Summit. Monday, March.
Positive
Seeking Alpha
1 month ago
IDEXX Laboratories And Its Real Value
IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years.
Positive
The Motley Fool
1 month ago
Why Idexx Labs Stock Rocketed Higher This Week
Shares of leading pet healthcare diagnostics provider Idexx Laboratories (IDXX -1.70%) were up by 9% this week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence.
Positive
Seeking Alpha
1 month ago
IDEXX Laboratories: I See Pet Healthcare As An Interesting Market For The Future
IDEXX Laboratories is poised for growth in the pet healthcare market, driven by an aging pet population and strong pet-owner bonds. IDEXX's comprehensive ecosystem, including AI-driven diagnostics and software, enhances veterinary practices and pet health monitoring, creating significant value for pet owners. IDEXX's strong balance sheet, shareholder-friendly capital allocation, and high ROIC of 32% indicate robust financial health and competitive advantage.
Positive
Barrons
1 month ago
Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.
Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street.
Neutral
Seeking Alpha
1 month ago
IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Company Participants Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & Companion Animal Group Finance Jay Mazelsky - President & Chief Executive Officer Conference Call Participants Erin Wright - Morgan Stanley Chris Schott - JPMorgan Michael Ryskin - Bank of America Jon Block - Stifel Daniel Clark - Leerink Partners Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' Fourth Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded.
Charts implemented using Lightweight Charts™